Swiss Chems: Evidence & Transparency Review
A source-led review of Swiss Chems that separates current supplier quality claims from indexed certificates and independent laboratory results.
At a glance
| Criterion | Status | What we found |
|---|---|---|
| Supplier testing claim | Public | Swiss Chems states that every batch is tested and that lot-specific COAs are available on request. |
| Indexed COA coverage | Substantial but incomplete | Peppers.market currently lists 13 indexed vendor+peptide documents covering 10 current matched documents in its summary, while noting that document coverage is not proof of batch identity. |
| Named laboratory evidence | Mixed | Current indexed records include Janoshik Analytical for several certificates, while other records are labelled SWISSCHEMS. |
| Independent testing | Mixed results | Finnrick reports 10 tests, 4 passes and 6 fails. TitrateLab reports 11 third-party certificates with 82.9% mean measured purity and three results below 90%. |
| Recent indexed results | Strong in selected batches | Examples include BPC-157 at 99.94%, Ipamorelin at 99.86%, Melanotan II at 99.69% and CJC-1295 no-DAC at 99.84% in indexed documents. |
| Overall evidence | Conflicted | Current vendor-published/secondary records contain many high-purity results, but independent historical testing contains significant failures and low-purity CJC-1295 results. |
| Final Peptide Choice Score | Not yet assigned | The evidence is too heterogeneous for a defensible single score until current-lot documents are systematically sampled and reconciled. |
1. Current supplier claims
Swiss Chems' current quality-assurance page says all batches are tested using validated analytical methods, that a lot-specific COA is available on request, and that products meet a stated minimum purity specification where applicable. It also describes a third-party testing process for customer quality claims.
These are supplier claims. Our methodology does not treat a guarantee or testing policy as laboratory evidence until the underlying documents can be inspected and attributed.
2. Current indexed COA trail
A current third-party index lists certificates linked to Swiss Chems products. Examples include a BPC-157 document printed June 25, 2026 with lot ED9319 and reported purity 99.94%, an Ipamorelin document dated June 16, 2026 at 99.86%, Melanotan II at 99.69%, IGF-LR3 at 99.36%, MOTS-c at 99.62%, CJC-1295 no-DAC at 99.84%, and Thymosin Alpha-1 at 98.60%.
Several of those records identify Janoshik Analytical; others are labelled simply SWISSCHEMS. We therefore distinguish laboratory-attributed documents from vendor-labelled records rather than combining them into a single “third-party tested” bucket.
3. Independent testing tells a more mixed story
Finnrick currently lists 10 tests, 4 passes and 6 fails for Swiss Chems. Its summary says the strongest evidence is in Ipamorelin and BPC-157, while CJC-1295 shows repeated purity misses and underfills.
TitrateLab's independent review tracks 11 third-party certificates from April 2025 through July 2026. It reports an average measured purity of 82.9%, with 8 of 11 results at or above 90% and 3 below 90%. Its lowest reported CJC-1295 results are 51.69%, 54.44% and 57.25%.
These results are historical and sample-dependent. They should not be presented as proof that current inventory is poor, but they are important enough that a high current COA average cannot be treated as the whole story.
4. A useful example of document-level verification
PeptideBenchmark preserves a June 12, 2026 Enclomiphene certificate attributed to Janoshik Analytical, report number 169033, with lot F26HGEnc. The record says the laboratory verification surface responded successfully, but the archive did not extract a purity or identity result from the document. This is a good example of why “certificate exists” and “certificate proves a particular analytical result” are separate claims.
5. Evidence strengths
- Swiss Chems currently publishes a detailed quality-assurance policy with lot-specific COA claims.
- Recent indexed certificates include identifiable lots, dates and several named laboratories.
- Some recent indexed purity results are very high, including BPC-157, Ipamorelin and CJC-1295 no-DAC examples.
- There is enough external testing history to identify product-specific patterns rather than relying solely on marketing statements.
Limitations & open questions
- Independent testing results vary sharply by compound and date.
- Current indexed COAs do not cover the entire tracked catalogue.
- Some certificates are labelled as vendor-generated rather than clearly attributable to an external laboratory.
- Historical low results should be investigated against batch, date and product changes before drawing conclusions about current stock.
- We have not independently established the scope/accreditation of every named laboratory for every method appearing in the records.
6. Why there is no final numerical score yet
Swiss Chems is exactly the kind of supplier where a single number can be misleading. One evidence set shows many recent high-purity certificates, while independent testing contains serious low-purity results, especially for CJC-1295. A rigorous score therefore needs to separate current documentary coverage from historical analytical performance and should not average incompatible samples blindly.
We will assign a final Peptide Choice Score only after a systematic current-lot sample has been reviewed using the same evidence hierarchy applied to Ascension, Limitless and American Peptides.
Sources reviewed
Commercial relationship
Peptide Choice Guide may disclose any affiliate relationship separately if one exists. Commercial relationships do not increase an editorial score.